Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rebus
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer|Glioblastoma|Hepatocellular Carcinoma|Renal Cell Carcinoma
Phase 1: Skin Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Single Patient IND | N/A |
No longer available |
Hepatocellular Carcinoma |
None |
2019-03-20 |
Treatments |
|
| G-202-001 | P1 |
Completed |
Skin Cancer |
2012-12-01 |
2019-03-19 |
Treatments |
|
| G-202-008 | P2 |
Withdrawn |
Glioblastoma |
2019-10-01 |
2022-03-17 |
Primary Endpoints|Treatments |
|
| G-202-004 | P2 |
Completed |
Glioblastoma |
2016-12-01 |
2024-05-22 |
Primary Endpoints |
|
| G-202-006 | P2 |
Completed |
Renal Cell Carcinoma |
2016-12-01 |
2019-03-20 |
Treatments |
|
| G-202-005 | P2 |
Completed |
Prostate Cancer |
2016-12-01 |
2019-03-20 |
Treatments |
|
| G-202-003 | P2 |
Completed |
Hepatocellular Carcinoma |
2015-03-01 |
2019-03-19 |
Treatments |
|
| G202-002 | P2 |
Withdrawn |
Prostate Cancer |
2015-01-01 |
2019-03-19 |
Treatments |
|
| 2011-002149-36 | P2 |
Terminated |
Prostate Cancer |
2013-08-19 |
2022-03-13 |
Treatments |